WINT
WINT clinical trials: WINDTREE THERAPEUTICS INC /DE/
Every trial on ClinicalTrials.gov where WINDTREE THERAPEUTICS INC /DE/ is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 17
- Trials linked
- 14
- As lead sponsor
- 3
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
WINT on the catalyst calendar · WINT registry changes
- Primary completion Jul 28, 2025ActualPhase 1/Phase 2NCT05975021A Safety and Efficacy Trial of Istaroxime for Cardiogenic Shock Stage CWindtree Therapeutics · Cardiogenic ShockActive, not recruitingWINTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 26, 2024ActualPhase 2NCT04325035The Safety and Efficacy of Istaroxime for Pre-Cardiogenic ShockWindtree Therapeutics · Cardiogenic ShockCompletedWINTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 20, 2022ActualPhase 2NCT04389671The Safety and Preliminary Tolerability of Lyophilized Lucinactant in Adults With Coronavirus Disease 2019 (COVID-19)Windtree Therapeutics · COVID-19CompletedWINTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 31, 2021ActualPhase 2NCT04264156A Safety and Efficacy Study of Lucinactant for Inhalation in Preterm Neonates 26 to 32 Weeks Gestational AgeWindtree Therapeutics · Respiratory Distress Syndrome, NewbornTerminatedWINTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 14, 2018ActualPhase 2NCT02617446The Clinical Study of the Safety and Efficacy of Istaroxime in Treatment of Acute Decompensated Heart FailureWindtree Therapeutics · Acute Decompensated Heart FailureCompletedWINTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 8, 2018ActualPhase 2NCT03217825Antihypertensive Effect of Different Doses of Rostafuroxin in Comparison With LosartanWindtree Therapeutics · HypertensionCompletedWINTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2017ActualPhase 2NCT02636868The Safety and Efficacy of Lucinactant for Inhalation in Premature Neonates 26 to 32 Weeks Gestational AgeWindtree Therapeutics · Respiratory Distress SyndromeCompletedWINTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 31, 2017ActualPhase 2NCT02528318Trial To Assess The Safety And Tolerability Of Lucinactant For Inhalation In Preterm Neonates 26 to 28 Weeks PMAWindtree Therapeutics · Respiratory Distress SyndromeTerminatedWINTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2006ActualPhase 2NCT00215553KL₄Surfactant Treatment in Patients With ARDSWindtree Therapeutics · Acute Respiratory Distress SyndromeTerminatedWINTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2015ActualPhase 2NCT02074059Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature NeonatesWindtree Therapeutics · Respiratory Distress SyndromeCompletedWINTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2005ActualPhase 2NCT00807235Feasibility Study of Aerosolized Surfaxin in the Prevention of Respiratory Distress Syndrome (RDS) in Premature InfantsWindtree Therapeutics · Respiratory Distress SyndromeTerminatedWINTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2006ActualPhase 2NCT00215540SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants.Windtree Therapeutics · Respiratory Distress Syndrome, NewbornTerminatedWINTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2010ActualPhase 2NCT00578734Lucinactant for Treatment of Acute Hypoxemic Respiratory Failure in Children up to Two Years OldWindtree Therapeutics · Acute Hypoxemic Respiratory FailureCompletedWINTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2002ActualPhase 3NCT00004500Phase III Randomized Study of Lucinactant in Full Term Newborn Infants With Meconium Aspiration SyndromeWindtree Therapeutics · Meconium AspirationTerminatedWINTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2025Sponsor estimatePhase 1NCT04706962TH1902 in Patients With Advanced Solid TumorsTheratechnologies · Solid TumorActive, not recruitingWINTCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2010ActualPhase 2NCT00934362Effect of Lucinactant on Mucus Clearance in Cystic Fibrosis Lung DiseaseUniversity of North Carolina, Chapel Hill · Cystic FibrosisCompletedWINTCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT00295230Effects of Volume Guarantee With Pressure Supported vs. Synchronized Intermittent Mandatory Ventilation in VLBW InfantsChildren's Hospitals and Clinics of Minnesota · Respiratory Distress SyndromeSuspendedWINTCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 17 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner